{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:40Z","timestamp":1787019580966,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Active malignancy is a known prothrombotic state, first described by Armand Trousseau as thrombophlebitis occurring in a patient with metastatic gastric cancer. The most common presentation of cancer-associated thrombosis (CAT) is venous thromboembolism, inclusive of deep venous thrombosis and pulmonary embolism. With advances in survival of many cancers, the incidence of CAT is increasing, and an estimated 15% to 20% of all patients with cancer will experience venous thromboembolism during their treatment. Consequently, management and prevention strategies for CAT are paramount for comprehensive clinical care of patients with active malignancy. Direct oral anticoagulants, which have fixed drug dosing, few drug-drug interactions, lack of monitoring requirements, and ease of oral administration, have emerged as the preferred option for CAT, with significant clinical trial data supporting their use. Here, we review the current treatment and prevention paradigms for patients with CAT, the specific role of direct oral anticoagulants for CAT, and ongoing challenges in CAT treatment.<\/jats:p>","DOI":"10.1182\/hematology.2025000690","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:55Z","timestamp":1764943855000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["No shots needed: direct oral anticoagulants in cancer-associated thrombosis\u201410-year follow-up"],"prefix":"10.1182","volume":"2025","author":[{"given":"Ruchi","family":"Desai","sequence":"first","affiliation":[{"name":"1 Massey Comprehensive Cancer Center at Virginia Commonwealth University, Division of Hematology, Oncology, and Palliative Care, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jaglal","sequence":"additional","affiliation":[{"name":"2 Department of Ambulatory Hematology and Oncology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"suppl 1","key":"2025120616355466700_hem2025000690C1","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(16)30092-5","article-title":"Cancer associated thrombosis: risk factors and outcomes","volume":"140","author":"Eichinger","year":"2016","journal-title":"Thromb Res"},{"issue":"10","key":"2025120616355466700_hem2025000690C2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"issue":"suppl 1","key":"2025120616355466700_hem2025000690C3","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"Lyman","year":"2018","journal-title":"Thromb Res"},{"issue":"14","key":"2025120616355466700_hem2025000690C4","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2025120616355466700_hem2025000690C5","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies\u2014TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"Wang","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025120616355466700_hem2025000690C6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"2025120616355466700_hem2025000690C7","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"2025120616355466700_hem2025000690C8","doi-asserted-by":"crossref","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025120616355466700_hem2025000690C9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CEOR.S39964","article-title":"Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States","volume":"5","author":"Khorana","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"2025120616355466700_hem2025000690C10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"2025120616355466700_hem2025000690C11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejvs.2018.11.004","article-title":"Editor's choice\u2014a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer","volume":"57","author":"Kirkilesis","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"2025120616355466700_hem2025000690C12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616355466700_hem2025000690C13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2025120616355466700_hem2025000690C14","first-page":"CD008077","article-title":"Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity","volume":"11","author":"Mohammady","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2025120616355466700_hem2025000690C15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2025120616355466700_hem2025000690C16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"2025120616355466700_hem2025000690C17","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"2025120616355466700_hem2025000690C18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2025120616355466700_hem2025000690C19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2025120616355466700_hem2025000690C20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"24","key":"2025120616355466700_hem2025000690C21","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"17","key":"2025120616355466700_hem2025000690C22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2025120616355466700_hem2025000690C23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2018-99-118808","article-title":"Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial","volume":"132","author":"McBane","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2025120616355466700_hem2025000690C24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"7","key":"2025120616355466700_hem2025000690C25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2025120616355466700_hem2025000690C26","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616355466700_hem2025000690C27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"2025120616355466700_hem2025000690C28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2025120616355466700_hem2025000690C29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616355466700_hem2025000690C30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M22-1258","article-title":"Anticoagulant therapy for cancer-associated thrombosis: a cost-effectiveness analysis","volume":"176","author":"Gulati","year":"2023","journal-title":"Ann Intern Med"},{"issue":"5","key":"2025120616355466700_hem2025000690C31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"issue":"2","key":"2025120616355466700_hem2025000690C32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"2025120616355466700_hem2025000690C33","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2025120616355466700_hem2025000690C34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025120616355466700_hem2025000690C35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025120616355466700_hem2025000690C36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2025120616355466700_hem2025000690C37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025120616355466700_hem2025000690C38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The significance of drug-drug and drug-food interactions of oral anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"2025120616355466700_hem2025000690C39","doi-asserted-by":"crossref","first-page":"102194","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"8","key":"2025120616355466700_hem2025000690C40","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"Mah\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2025120616355466700_hem2025000690C41","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025120616355466700_hem2025000690C42","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2025120616355466700_hem2025000690C43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616355466700_hem2025000690C44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025120616355466700_hem2025000690C45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616355466700_hem2025000690C46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616355466700_hem2025000690C47","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"2025120616355466700_hem2025000690C48","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2025120616355466700_hem2025000690C49","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jth.15823","article-title":"Direct oral anticoagulants after bariatric surgery\u2014what is the evidence?","volume":"20","author":"Leong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2025120616355466700_hem2025000690C50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2017.11.006","article-title":"The effect of bariatric surgery on direct-acting oral anticoagulant drug levels","volume":"163","author":"Rottenstreich","year":"2018","journal-title":"Thromb Res"},{"issue":"3","key":"2025120616355466700_hem2025000690C51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"2025120616355466700_hem2025000690C52","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.3390\/ijms22168531","article-title":"The clinical significance of drug-food interactions of direct oral anticoagulants","volume":"22","author":"Grze\u015bk","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/80\/2470343\/80desai.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/80\/2470343\/80desai.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:36:04Z","timestamp":1765056964000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/80\/556839\/No-shots-needed-direct-oral-anticoagulants-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000690","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}